Incidence of Peripheral Neuropathy in Elderly Patients with Metastatic Breast Cancer Receiving Eribulin (Eri) or Ixabepilone (Ixa) Chemotherapy

被引：0
|
作者：
Lee, L. [1 ]
Vahdat, L. [1 ]
机构：
[1] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2011年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S176 / S177
页数：2
相关论文
共 50 条
  • [1] Comparison of the incidence of peripheral neuropathy (PN) with eribulin versus ixabepilone (IXA) in metastatic breast cancer (MBC) patients: A randomized phase II study.
    Vahdat, Linda T.
    Garcia, Agustin
    Vogel, Charles L.
    Pellegrino, Christine M.
    Lindquist, Deborah L.
    Sparano, Joseph A.
    Gopalakrishna, Prashanth
    Iannotti, Nicholas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [2] Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
    Vahdat, Linda T.
    Garcia, Agustin A.
    Vogel, Charles
    Pellegrino, Christine
    Lindquist, Deborah L.
    Iannotti, Nicholas
    Gopalakrishna, Prashanth
    Sparano, Joseph A.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (02) : 341 - 351
  • [3] Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
    Linda T. Vahdat
    Agustin A. Garcia
    Charles Vogel
    Christine Pellegrino
    Deborah L. Lindquist
    Nicholas Iannotti
    Prashanth Gopalakrishna
    Joseph A. Sparano
    Breast Cancer Research and Treatment, 2013, 140 : 341 - 351
  • [4] Comparison of the Incidence of Peripheral Neuropathy with Eribulin Mesylate Versus Ixabepilone in Metastatic Breast Cancer Patients: A Randomized Phase II Study.
    Vandat, L.
    Gopalakrishna, P.
    Garcia, A. A.
    Vogel, C.
    Pellegrino, C.
    Lindquist, D.
    Iannotti, N.
    CANCER RESEARCH, 2011, 71
  • [5] Incidence and resolution of eribulin-induced peripheral neuropathy (IRENE) in patients with locally advanced or metastatic breast cancer
    Schmidt, M.
    Jackisch, C.
    Hesse, T.
    Hoffmann, O.
    Heinrich, B. J.
    Park-Simon, T-W
    Grischke, E-M.
    Weide, R.
    Mueller-Huesmann, H.
    Welslau, M.
    Wu, J.
    Schmitz, H.
    Engelbrecht, C.
    Lueck, H-J.
    ANNALS OF ONCOLOGY, 2021, 32 : S496 - S497
  • [6] Ixabepilone-associated peripheral neuropathy in metastatic breast cancer patients and its effects on the ultrastructure of neurons
    Jain, S.
    Carlson, K.
    Chuang, E.
    Cigler, T.
    Moore, A.
    Donovan, D.
    Lam, C.
    Cobham, M. V.
    Schneider, S.
    Ramnarain, A.
    Carey, B.
    Ward, M.
    Lane, M.
    Strickland, S.
    Vandat, L.
    CANCER RESEARCH, 2012, 72
  • [7] Peripheral neuropathy (PN) in patients (pts) with metastatic breast cancer treated with eribulin: Resolution and association with efficacy
    Kaufman, Peter
    Olivo, Martin
    He, Yi
    McCutcheon, Susan
    Vandat, Linda
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [8] INDIRECT COSTS AMONG METASTATIC BREAST CANCER PATIENTS RECEIVING ERIBULIN
    Wan, Y.
    Copher, R.
    Corman, S.
    Abouzaid, S.
    Gao, X.
    VALUE IN HEALTH, 2015, 18 (03) : A202 - A202
  • [9] Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer
    Tanabe, Yuko
    Hashimoto, Kenji
    Shimizu, Chikako
    Hirakawa, Akihiro
    Harano, Kenichi
    Yunokawa, Mayu
    Yonemori, Kan
    Katsumata, Noriyuki
    Tamura, Kenji
    Ando, Masashi
    Kinoshita, Takayuki
    Fujiwara, Yasuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (01) : 132 - 138
  • [10] Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer
    Yuko Tanabe
    Kenji Hashimoto
    Chikako Shimizu
    Akihiro Hirakawa
    Kenichi Harano
    Mayu Yunokawa
    Kan Yonemori
    Noriyuki Katsumata
    Kenji Tamura
    Masashi Ando
    Takayuki Kinoshita
    Yasuhiro Fujiwara
    International Journal of Clinical Oncology, 2013, 18 : 132 - 138
12345